Sanofi: to collaborate with Translate Bio against COVID-19
(CercleFinance.com) - Sanofi has announced that its lobal vaccines entity, Sanofi Pasteur, is collaborating with Translate Bio, to develop a novel mRNA vaccine candidate against COVID-19.
Translate Bio will use its mRNA platform to research, design and produce several vaccine candidates, while Sanofi will provide vaccine expertise and support to its external research networks for their development potential.
Translate Bio has established 100 gram single-batch production with its clinical-stage mRNA therapeutics platform. The construction of dedicated manufacturing space is underway, having been entrusted to a subcontracting partner, to accommodate at least two 250-gram batches per month.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
Translate Bio will use its mRNA platform to research, design and produce several vaccine candidates, while Sanofi will provide vaccine expertise and support to its external research networks for their development potential.
Translate Bio has established 100 gram single-batch production with its clinical-stage mRNA therapeutics platform. The construction of dedicated manufacturing space is underway, having been entrusted to a subcontracting partner, to accommodate at least two 250-gram batches per month.
Copyright (c) 2020 CercleFinance.com. All rights reserved.